HC Wainwright Forecasts Evolus’ Q4 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS) – Equities researchers at HC Wainwright reduced their Q4 2025 earnings estimates for shares of Evolus in a research report issued on Tuesday, February 3rd. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $68.97 million during the quarter, compared to the consensus estimate of $91.23 million.

Several other equities research analysts have also recently weighed in on EOLS. BTIG Research reduced their price target on Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Mizuho dropped their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, December 1st. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Evolus has a consensus rating of “Moderate Buy” and a consensus price target of $18.17.

Evolus Stock Performance

EOLS stock opened at $4.70 on Wednesday. Evolus has a fifty-two week low of $4.56 and a fifty-two week high of $17.12. The company has a market capitalization of $304.65 million, a price-to-earnings ratio of -5.11 and a beta of 1.11. The business’s 50 day moving average price is $6.16 and its two-hundred day moving average price is $6.76.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the transaction, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently modified their holdings of the business. Manchester Capital Management LLC bought a new position in shares of Evolus during the second quarter valued at $26,000. State of Alaska Department of Revenue purchased a new stake in shares of Evolus during the 3rd quarter valued at about $26,000. Wexford Capital LP purchased a new stake in shares of Evolus during the 3rd quarter valued at about $37,000. Tower Research Capital LLC TRC grew its stake in shares of Evolus by 340.2% in the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after acquiring an additional 5,691 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in shares of Evolus during the third quarter valued at approximately $48,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.